Managing NeoVirTech SAS (6 FTE). Successfully closed multi year programs from BPI France, TTOs and private companies from hit discovery to animal testing in infectious conditions. Currently managing grants from région Occitanie (2020-2021, development of disinfection procedures againts SARS-CoV-2) and Defence innovation agency for the Army Ministry (2019-2023, medical counter-measures against poxviruses outbreak) Distinguished Member of the World Society of Virology At NeoVirTech, we believe everyone can have access to state-of-the-art virology techniques. We are focusing our activities on antiviral discovery, study of oncolytic and gene therapy products and quantification of disinfection procedures (physical, chemical, radiative) using a large collection of pathogenous viruses impacting the human, animal and biodefence market. We work in BSL2 lab (Herpes, adenovirus, ...), BSL2+ level (influenza H1N1, RSV, rhinovirus) and BSL3 confinement (highly pathogenous influenza, SARS-CoV-2). With our ANCHOR technology, we can directly visualize virus infection and replication in living cells without fixation, extraction or reagents. Customers use our service to identify rapidly and efficiently new antiviral molecules, calibrate and validate disinfection procedures, investigate oncolytic virus behavior or understand the biology of gene therapy vectors. Our technologies relies on state off the art microscopy platform, providing our customers qualitative images for communication and marketing operations. If viruses are of your concern, contact us: contact@neovirtech.com More informations: www.neovirtech.com